Heart transplantation in a case of juvenile hereditary haemochromatosis followed up by MRI and endomyocardial biopsies.
Cardiac involvement in hereditary haemochromatosis (HH) is a poor prognostic sign and is the main cause of death in the juvenile form. The treatment of choice is iron removal therapy by phlebotomy, but treatment by iron chelation (desferrioxamine) has been recommended in cases with severe cardiac symptoms. We describe here the first case of juvenile HH undergoing heart transplantation, which became necessary despite intensive iron removal therapy by phlebotomy and treatment by desferrioxamine. Throughout the course the myocardial iron content was monitored by endomyocardial biopsies and by magnetic resonance imaging (MRI). At the last follow-up, 18 months after transplantation, the myocardial iron content in the transplanted heart was still within reference ranges by biochemical determination and MRI and the patient's condition was completely satisfactory. In conclusion, heart transplantation should be considered in cases of severe juvenile HH. In the follow-up of these patients MRI may be a useful supplement.
Jensen
P D
PD
Department of Medicine, Aarhus Amtssygehus, Denmark.
Bagger
J P
JP
Jensen
F T
FT
Baandrup
U
U
Christensen
T
T
Ellegaard
J
J
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D003676:Deferoxamine / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy; D005293:Ferritins / Q000097:blood; D005500:Follow-Up Studies; D016027:Heart Transplantation / Q000473:pathology / Q000502:physiology; D006432:Hemochromatosis / Q000503:physiopathology / Q000628:therapy*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D013997:Time Factors
D015415:Biomarkers; D006454:Hemoglobins; D005293:Ferritins; D000410:Alanine Transaminase; D003676:Deferoxamine